Peptide-based treatment for autoimmune diseases: Learning how to handle a double-edged sword

Journal of Clinical Investigation

Volumn 111, Issue 9, 2003, Pages 1280-1282

  Pugliese, Alberto ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; INSULIN; INSULIN PEPTIDE B9 23; PEPTIDE HORMONE; PHOSPHATASE; PROINSULIN; PROTEIN IA 2; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; NOTE; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0037651223     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI18395     Document Type: Note

References (21)

1. Nepom, G.T. 2002. Therapy of autoimmune diseases: clinical trials and new biologics. Curr. Opin. Immunol. 14:812-815.
2. Liu, E., and Eisenbarth, G.S. 2002. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol. Metab. Clin. North Am. 31:391-410.
3. Daniel, D., and Wegmann, D.R. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. U. S. A. 93:956-960.
4. Wong, F.S., et al. 1999. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5:1026-1031.
5. Chen, W., et al. 2001. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J. Immunol. 167:4926-4935.
6. Rudy, G., et al. 1995. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol. Med. 1:625-633.
7. Muir, A., Schatz, D., and Maclaren, N. 1993. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab. Rev. 9:279-287.
8. Bergerot, I., Fabien, N., Maguer, V., and Thivolet, C. 1994. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J. Autoimmun. 7:655-663.
9. Maron, R., Guerau-de-Arellano, M., Zhang, X., and Weiner, H.L. 2001. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J. Autoimmun. 16:21-28.
10. Atkinson, M., Maclaren, N., Luchetta, R., and Burr, I. 1990. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933-937.
11. Harrison, L.C., Dempsey-Collier, M., Kramer, D.R., and Takahashi, K. 1996. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184:2167-2174.
12. Diabetes Prevention Trial-Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346:1685-1691.
13. Harrison, L.C., et al. 1999. Intranasal insulin trial (INIT) in preclinical type 1 diabetes. Diabetes. 48:A206.(Abstr.)
14. Tian, J., Olcott, A.P., and Kaufman, D.L. 2002. Antigen-based immunotherapy drives the precocious development of autoimmunity. J. Immunol. 169:6564-6569.
15. Cetkovic-Cvrlje, M., et al. 1997. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens. Diabetes. 46:1975-1982.
16. Liu, E., et al. 2002. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 110:1021-1027. doi:10.1172/JCI200215488.
17. Pedotti, R., et al. 2003. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol. 4:2.
18. Martinez, N.R., et al. 2003. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin. Invest. 111:1365-1371. doi:10.1172/JCI200317166.
19. Das, P., Abraham, R., and David, C. 2000. HLA transgenic mice as models of human autoimmune diseases. Rev. Immunogenet. 2:105-114.
20. Wong, F.S., Moustakas, A.K., Wen, L., Papadopoulos, G.K., and Janeway, C.A., Jr. 2002. Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 99:5551-5556.
21. Wong, F.S., and Wen, L. 2003. The study of HLA class II and autoimmune diabetes. Curr. Mol. Med. 3:1-15.